These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22151023)

  • 1. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
    Simsek S; Schalkwijk CG; Wolffenbuttel BH
    Diabet Med; 2012 May; 29(5):628-31. PubMed ID: 22151023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and glycaemic control--a cause for concern?
    Hitman GA
    Diabet Med; 2012 May; 29(5):557. PubMed ID: 22506936
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
    Koshel'skaia OA; Vinnitskaia IV; Konko TIu; Kravchenko ES; Suslova TE; Karpov RS
    Kardiologiia; 2015; 55(3):67-74. PubMed ID: 26320293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –.
    Ogawa H; Matsui K; Saito Y; Sugiyama S; Jinnouchi H; Sugawara M; Masuda I; Mori H; Waki M; Yoshiyama M; Watada H
    Circ J; 2014; 78(10):2512-5. PubMed ID: 25186922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
    Park JS; Kim YJ; Choi JY; Kim YN; Hong TJ; Kim DS; Kim KY; Jeong MH; Chae JK; Oh SK; Seong IW
    Korean J Intern Med; 2010 Mar; 25(1):27-35. PubMed ID: 20195400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Kurabayashi M; Yamazaki T;
    J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
    Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
    Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin-induced arrest in progression of renal disease.
    Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
    Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
    Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
    van Himbergen TM; Matthan NR; Resteghini NA; Otokozawa S; Ai M; Stein EA; Jones PH; Schaefer EJ
    J Lipid Res; 2009 Apr; 50(4):730-9. PubMed ID: 19043140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
    Thongtang N; Ai M; Otokozawa S; Himbergen TV; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
    Am J Cardiol; 2011 Feb; 107(3):387-92. PubMed ID: 21257003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.